Loading
EB
Eiger BioPharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 02 Nov 2023.
Eiger BioPharmaceuticals, Inc.: what insiders have been doing
Eiger BioPharmaceuticals, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Nothing new has been filed by managers of Eiger BioPharmaceuticals, Inc. in twelve months, the latest record being from 2 November 2023.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
22
Thresholds
n/a
Buy Volume
€192,402
4 ops. · all time
Sell Volume
€108,203
7 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$13.6M
Net income-US$64.5M-475.3% margin
Last declaration on 2 November 2023
Declarations22 total
11,987 shares@ US$0.2625100.0% of flowCommon StockSEC:0001140361-23-051263:0
Canonical exit: 29 Jan 2024 (T+90)
11,987 shares@ US$0.2625100.0% of flowCommon StockSEC:0001140361-23-051260:0
Canonical exit: 29 Jan 2024 (T+90)
2,520 shares@ US$1.0710.3% of flowCommon StockSEC:0001140361-23-012884:0
50,000 shares@ US$1.431672.7% of flowCommon StockSEC:0001567619-23-001284:0
Canonical exit: 23 Apr 2023 (T+90)
5,000 shares@ US$1.2208100.0% of flowCommon StockSEC:0001567619-23-000069:0
100,000 shares@ US$1.2795100.0% of flowCommon StockSEC:0001140361-22-047070:0
Canonical exit: 22 Mar 2023 (T+90)
22,500 shares@ US$1.16927.3% of flowCommon StockSEC:0001140361-22-047071:0
5,000 shares@ US$9.8061100.0% of flowCommon StockSEC:0001567619-22-016461:0
2,266 shares@ US$5.5973100.0% of flowCommon StockSEC:0001567619-22-006948:0
1,657 shares@ US$5.597347.5% of flowCommon StockSEC:0001567619-22-006947:0
6,000 shares0Common StockSEC:0001140361-22-009259:0
6,000 shares0Common StockSEC:0001140361-22-009254:0
6,000 shares0Common StockSEC:0001140361-22-009261:0
6,000 shares0Common StockSEC:0001140361-22-009257:0
6,000 shares0Common StockSEC:0001140361-22-009255:0
16,000 shares0Common StockSEC:0001140361-22-009260:0
47,000 shares0Common StockSEC:0001140361-22-009256:0
6,000 shares0Common StockSEC:0001140361-22-009263:0
24,000 shares0Common StockSEC:0001140361-22-009262:0
6,000 shares0Common StockSEC:0001140361-22-009264:0
1,560 shares@ US$4.950138.3% of flowCommon StockSEC:0001567619-22-001050:0
22 of 22 declarations
About Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. From an investor’s perspective, Eiger has historically been a rare-disease focused story built around highly targeted assets rather than a broad diversified platform. The company’s strategy centered on developing therapies for severe unmet-need conditions, initially around hepatitis delta virus (HDV) and later around select genetic and endocrine disorders. Eiger’s headquarters were in Palo Alto, California, placing it in one of the most established biotech clusters in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1305253/000130525323000005/eigr-20221231.htm?utm_source=openai))
Eiger’s core business model combined clinical development, regulatory execution, and, at times, commercialization of niche orphan-disease assets. Its best-known marketed product was Zokinvy® (lonafarnib), approved in the United States to reduce the risk of mortality in Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies. In January 2024, Eiger and partner AnGes also secured marketing approval for Zokinvy in Japan, underscoring the international dimension of the asset. In parallel, the company advanced avexitide, a first-in-class GLP-1 antagonist being developed for post-bariatric hypoglycemia and other forms of hyperinsulinemic hypoglycemia. That program attracted strategic interest from larger biotech buyers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1305253/000162828024015297/eigr-20231231.htm?utm_source=openai))
Read moreShow less
Competitively, Eiger was differentiated by focus rather than scale. The company operated in extremely narrow therapeutic niches where clinical and regulatory success can create meaningful value, but where dependence on a small number of programs also raises execution, financing, and concentration risk. This is a classic small-cap biotech profile: high optionality, but also high vulnerability to clinical setbacks, limited commercialization scale, and capital structure stress. Eiger’s recent history makes that risk profile particularly visible. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1305253/000119312524083560/d821503dnt10k.htm?utm_source=openai))
The most important recent developments occurred in 2024. On April 1, 2024, Eiger and its subsidiaries filed voluntary Chapter 11 petitions in the United States Bankruptcy Court for the Northern District of Texas. Following a court-supervised sale process, the company began monetizing key assets, including Zokinvy and avexitide, through transactions approved or announced during 2024. For equity analysts, that means Eiger should be viewed less as a conventional operating biotech and more as a restructuring and asset-monetization case, where residual value depends on legal outcomes, asset sales, and the treatment of stakeholders. Any assessment of the stock should therefore be framed around balance-sheet risk, bankruptcy proceedings, and the fate of remaining assets rather than a standard commercial-growth narrative. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001305253/000119312524083403/d818699dex991.htm?utm_source=openai))
